Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAA-ACP + AuMQ is a combination nanomedicine formulation designed for drug delivery, likely in the context of cancer therapy, typically for carrying a payload such as a chemotherapeutic agent like doxorubicin in similar systems[3]. The components are: - **PAA-ACP** refers to poly(acrylic acid)-coated amorphous calcium phosphate nanoparticles. Poly(acrylic acid) (PAA) is a synthetic anionic polymer known for its water absorption and polyelectrolyte properties[1]. Amorphous calcium phosphate (ACP) serves as a biocompatible mineral phase often used in biomedical applications. - **AuMQ** likely refers to gold-based quantum dots or gold nanomaterials functionalized with quaternary ammonium groups or other moieties ("Q"), which are commonly used as imaging agents or for photothermal/photodynamic therapy. This combination is engineered to serve as a multifunctional drug delivery platform, potentially offering pH-responsive release (due to the ACP core and PAA coating), enhanced cellular uptake, and possibly additional imaging or therapeutic functions from the gold component. Such systems are under investigation primarily for targeted cancer chemotherapy and theranostics[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PAA-ACP + AuMQ.